Www.whonet.org



Cumulative Antibiogram, United Arab Emirates (2019) Cumulative Antimicrobial Susceptibility Report – Gram-negative BacteriaUnited Arab Emirates, 1 January to 31 December 2019, Percent susceptible isolates (%Sa), isolates from all sourcesc (N=45,026) Gram-negative BacteriaIsolatesβ-Lactams Penicillins Cephalosporins CarbapenemsAminoglycosidesFQOtherNAMPAMCTZPCZObCXMCTXCAZFEPIPMMEMETPAMKGENTOBCIPATMSXTNITcGram-negative bacteria (all)45,026?6991??70?8391959696898664687175c Haemophilus influenzaed9868490??95?????????92?77? Moraxella (Branh.) catarrhalise190?94??100?????????93?98?Enterobacteriaceae35,90229719329?75?83949798989088638070? Citrobacter koseri (diversus)719R9596917693?9699999899999896959982c Enterobacter cloacae951RR83R4175?9289989599959487848942c Enterobacter aerogenes (K. aer.)664RR86RR81?96649997100979590889420c Escherichia coli f20,734377594276670?7999999999898757776294c Klebsiella pneumoniae8,095R7989387078?8497979798938869798036c Klebsiella oxytoca225R8895?8594?9899999910097949084 g9278c Morganella morganii380RR96RR68?933999991008176489062R Proteus mirabilis1,097629299809491?95159897987985679361R Proteus vulgaris22R80g100gRR100g?100g24g100g100g100g94g?77g?65gR Providencia spp.96RR99R?91?10049989497788762?83R Salmonella spp. (non-typhoid)745769498??95?99??????80h?96? Salmonella Typhi/Paratyphi6871g88g96g??89h?92 h??????16h?79h? Serratia marcescens737RR97RR91?97819998999791899497R Shigella spp.87207298??52?84??????34?29?Non-fermenting Gram-neg. rods 7,667RR78???82817879R868382714674? Acinetobacter baumannii938RR71???68717675R84767571R83? Pseudomonas aeruginosa4,794RR91?RR87898485R9591958364RR Stenotrophomonas maltophiliai480RRR??R60?RRRRRR?R90?a The %S for each organism/antimicrobial combination was generated by including the first isolate only of that organism encountered on a given patient during 2018 (de-duplicated data). b CZO (cefazolin) data is from four hospitals only, i.e. not representative for Abu Dhabi. c NIT: Nitrofurantoin data from urine isolates only. d H. influenzae: LVX: 98 %S, CRO: 97 %S, AZM: no data, CLR: 98 %S (MIC). e M. catarrhalis: CLR no data, ERY 100 %S, AZM 99%, LVX 100 %Sg, TCY 91 %S. f E. coli (urinary tract isolates): FOS: 99 %S. g A small number of isolates were tested (N<30), and the percentage susceptible should be interpreted with caution. h Ciprofloxacin results for Salmonella spp. refer to extra-intestinal (non-stool) isolates only. i S. maltophilia: MNO: 99 %S, TCC: 80 %S.AMC=Amoxicillin/Clavulanic acid, AMK=Amikacin, AMP=Ampicillin, ATM=Aztreonam, AZM=Azithromycin, CAZ=Ceftazidime, CIP=Ciprofloxacin, CLR=Clarithromycin, CRO=Ceftriaxone, CTX=Cefotaxime, CXM=Cefuroxime, CZO=Cefazolin, ETP=Ertapenem, ERY=Erythromycin, FEP=Cefepime, FOS=Fosfomycin, GEN=Gentamicin, IPM=Imipenem, LVX=Levofloxacin, MEM=Meropenem, MNO=Minocycline, NIT=Nitrofurantoin, SXT=Trimethoprim/Sulfamethoxazole, TCC=Ticarcillin/Clavulanic acid, TCY=Tetracycline, TOB=Tobramycin, TZP=Piperacillin/Tazobactam.%S=Percent of isolates susceptible, FQ=Fluoroquinolones, MIC=Minimal inhibitory concentration data only (usually derived by antibiotic susceptibility testing platforms), except for H. influenzae and M. catarrhalis (disc diffusion data), N=Number, spp.=species, R=intrinsically resistant, (?) =No data available, small number of isolates tested (N<30), antimicrobial agent is not indicated, or not effective clinically. Interpretation standard: CLSI M100 ED29:2019. Presentation standard: CLSI M39-A4:2014. Data analysis: WHONET 2020 (20.6.5).Data source: United Arab Emirates Antimicrobial Resistance Surveillance System (ADPHC). Data shown is from 250 surveillance sites from public and private sector, including 79 hospitals and 171 ambulatory healthcare facilities. Version 1.1 (14/09/2020)Cumulative Antibiogram, United Arab Emirates (2019)Cumulative Antimicrobial Susceptibility Report – Gram-positive BacteriaUnited Arab Emirates, 1 January to 31 December 2019, Percent susceptible Isolates (%Sa), isolates from all sourcesb (N=27,002) Gram-positive BacteriaIsolatesβ-LactamsMacrolidesAminoglycosidesFQGlycopept.OtherNAMPPENAMCOXACROCTXERYCLIGENGEHSTHLVXMFXVANTECSXTNITbLNZTCYRIFQDAGram-positive organisms (all)27,002??????5679???79589998689899???Enterococcus spp.2,85294???RR?RR879577749898R9598??? Enterococcus faecalis2,179100???RR?RR879576719999R9797??R Enterococcus faecium17225???RR?RR839133?8789R3698??91Staphylococcus aureus12,049??64364??708691??677110010072991008710090 MSSA5,907??100100??769097??7277100100751001008910093 MRSA3,025??????567879??55561001006699100849979Coagulase-neg. staphylococci (CNS)2,073??34c34??357379??75709992829999829594 Staphylococcus epidermidis827??25c25??286868??485999897110099829594 Staphylococcus saprophyticus g265??27c27??387799??9999981009510098909694 Staphylococcus lugdunensis159??74c74??788094??99971001001001001009310098Streptococcus pneumoniae960?93d??97e94e5273???9599100?64?100619999Streptococcus pyogenes h2,414100f100??97986988???89?100???10078??Streptococcus agalactiae i4,13310096??99964551???88?99??9810015?99Streptococcus spp. (viridans group)545?58??88885179???89?99???9960??a The %S for each organism/antimicrobial combination was generated by including the first isolate only of that organism encountered on a given patient during 2018 (de-duplicated data). b NIT: Nitrofurantoin data from testing urine isolates only. c Extrapolated, based on Oxacillin. d Data shown is based on non-meningitis breakpoints for Pen G. Pen G (meningitis breakpoints/oral breakpoints): 44 %S. e CRO/CTX: Data shown is based on non-meningitis breakpoints f Extrapolated, based on Penicillin G g includes ss bovis and ss saprophyticus h includes Streptococcus, beta-haemolytic group A (GAS) i includes Streptococcus, group B (GBS)AMP=Ampicillin, AMC=Amoxicillin/Clavulanic acid, CLI=Clindamycin, CRO=Ceftriaxone, CTX=Cefotaxime, ERY=Erythromycin, GEH=Gentamicin, high-level, GEN=Gentamicin, LNZ=Linezolid, LVX=Levofloxacin, MFX=Moxifloxacin, NIT=Nitrofurantoin, OXA=Oxacillin, PEN=Penicillin G, QDA=Quinupristin/Dalfopristin, RIF=Rifampin, STH=Streptomycin, high-level, SXT=Trimethoprim/Sulfamethoxazole, TEC=Teicoplanin, TCY=Tetracycline, VAN=Vancomycin. %S=Percent of isolates susceptible, FQ=Fluoroquinolones, GAS=Group A streptococci, GBS=Group B streptococci, Glycopept.=Glycopeptides, MIC=Minimal inhibitory concentration data only (usually derived by antibiotic susceptibility testing platforms), MRSA=Oxacillin-resistant S. aureus, MSSA=Oxacillin-susceptible S. aureus, N=Number, spp.=species, R=intrinsically resistant, (?) =No data available, or small number of isolates tested (N<30), or antimicrobial agent is not indicated or not effective clinically. Interpretation standard: CLSI M100 ED29:2019. Presentation standard: CLSI M39-A4:2014. Data analysis: WHONET 2020 (20.6.5).Data source: United Arab Emirates Antimicrobial Resistance Surveillance System (ADPHC). Data shown is from 250 surveillance sites from public and private sector, including 79 hospitals and 171 ambulatory healthcare facilities. Version 1.1 (14/09/2020)Cumulative Antibiogram, United Arab Emirates (2019)Cumulative Antimicrobial Susceptibility Report – Candida spp.United Arab Emirates, 1 January to 31 December 2019Percent susceptible Isolates (%Sa), isolates from all sources (N=2,359)Isolates(N)Isolates (%)TriazolesPolyenesEchinocandinsFLUVORAMBbCAScMIFCandida spp.2,3591008170888994 Candida albicans1,193519383969998 Candida spp. (non-albicans)1,166496656808190 Candida tropicalis409179397999799 Candida parapsilosis24811767997100100 Candida glabrata227106?d997198 Candida lusitaniae512????? Candida krusei492??8672100 Candida auris e39228?696100 Other (non-albicans)1436?????aThe %S for each organism/antimicrobial combination was generated by including the first isolate of that organism encountered on a given patient (de-duplicated data). bAMB: based on EUCAST and CDC breakpoints (S≤1, R≥2) for C. albicans, C. glabrata, C. krusei, C.?parapsilosis, C. tropicalis, and C. auris (accounting for 83% of all Candida spp. Isolates). cCAS: Caspofungin susceptibility testing in vitro has been associated with significant inter-laboratory variability. dFor C. glabrata and Voriconazole, current data are insufficient to demonstrate a correlation between in vitro susceptibility testing and clinical outcome. eCandida auris breakpoints based on U.S. CDC. tentative MIC breakpoints.AMB=Amphotericin B, CAS=Caspofungin, FLU=Fluconazole, MIF=Micafungin, VOR=Voriconazole.%S=Percent of isolates susceptible, MIC=Minimal inhibitory concentration data only (usually derived by antibiotic susceptibility testing platforms), N=Number, spp.=species, R=intrinsically resistant, (?) =No data available, or very small number of isolates tested (N<10), or antimicrobial agent is not indicated or not effective clinically. Interpretation standard: CLSI M60 ED1:2017. For AMB: EUCAST v9.0:2019. Presentation standard: CLSI M39-A4:2014.Data source: United Arab Emirates Antimicrobial Resistance Surveillance System (ADPHC). Data shown is from 250 surveillance sites from public and private sector, including 79 hospitals and 171 ambulatory healthcare facilities. Version 1.1 (14/09/2020)Cumulative Antimicrobial Susceptibility Report – Mycobacterium tuberculosisUnited Arab Emirates, 1 January to 31 December 2019 Percent susceptible Isolates (%Sa), isolates from all sources (N=434) Isolates (N)RifampinEthambutolIsoniazidPyrazinamideStreptomycinMycobacterium tuberculosis complex5299698889490baThe %S for each organism/antimicrobial combination was generated by including the first isolate of that organism encountered on a given patient (de-duplicated data). b n=98 isolates only were tested for streptomycin. %S=Percent of isolates susceptible, N=Number.Data source: United Arab Emirates Antimicrobial Resistance Surveillance System (ADPHC). Data shown is from 250 surveillance sites from public and private sector, including 79 hospitals and 171 ambulatory healthcare facilities. Version 1.1 (14/09/2020) ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download